LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Pipeline Biosion has a robust pipeline of biologics, including its lead asset BSI-045B in Phase 3 trials, indicating strong potential for future commercial partnerships and licensing opportunities in oncology and immune-related therapies.

Strategic Collaborations Recent licensing agreements, such as the partnership with Aclaris Therapeutics and licensing with Tai Tianqing Pharmaceutical Group, showcase opportunities for joint development and regional commercialization, opening avenues for expanding market access and co-marketing strategies.

Global Footprint With operations in China, the US, and Australia, Biosion is positioned to leverage regional healthcare markets and tap into diverse patient populations, making it an attractive partner for companies aiming to expand clinical and commercial footprints.

Funding and Growth Receiving over 40 million USD in financing highlights strong investor confidence and provides resources for accelerated clinical development and potential partnership negotiations, especially in emerging biotech markets.

Recent Leadership The appointment of experienced executives like Kedan Lin as Chief Development Officer and President of Biosion US signals an organizational focus on advancing clinical programs and building strategic industry collaborations, which can facilitate sales efforts and partnership development.

Biosion Tech Stack

Biosion uses 8 technology products and services including Alibaba Cloud CDN, Microsoft 365, Nuxt.js, and more. Explore Biosion's tech stack below.

  • Alibaba Cloud CDN
    Content Delivery Network
  • Microsoft 365
    Email
  • Nuxt.js
    Javascript Frameworks
  • Element UI
    Javascript Frameworks
  • Vue.js
    Javascript Frameworks
  • Swiper
    Javascript Libraries
  • Node.js
    Programming Languages
  • Tengine
    Web And Application Servers

Media & News

Biosion's Email Address Formats

Biosion uses at least 1 format(s):
Biosion Email FormatsExamplePercentage
First.Last@biosion.comJohn.Doe@biosion.com
50%
First.Last@biosion.comJohn.Doe@biosion.com
50%

Frequently Asked Questions

Where is Biosion's headquarters located?

Minus sign iconPlus sign iconBiosion's main headquarters is located at Nanjing, Jiangsu 210061 China. The company has employees across 2 continents, including AsiaNorth America.

What is Biosion's official website and social media links?

Minus sign iconPlus sign iconBiosion's official website is biosion.com and has social profiles on LinkedInCrunchbase.

What is Biosion's SIC code NAICS code?

Minus sign iconPlus sign iconBiosion's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biosion have currently?

Minus sign iconPlus sign iconAs of March 2026, Biosion has approximately 24 employees across 2 continents, including AsiaNorth America. Key team members include Vp Of Finance: A. Z.Head Of Quality Management: S. M.Founder, Chairman And Ceo: M. C.. Explore Biosion's employee directory with LeadIQ.

What industry does Biosion belong to?

Minus sign iconPlus sign iconBiosion operates in the Biotechnology Research industry.

What technology does Biosion use?

Minus sign iconPlus sign iconBiosion's tech stack includes Alibaba Cloud CDNMicrosoft 365Nuxt.jsElement UIVue.jsSwiperNode.jsTengine.

What is Biosion's email format?

Minus sign iconPlus sign iconBiosion's email format typically follows the pattern of First.Last@biosion.com. Find more Biosion email formats with LeadIQ.

How much funding has Biosion raised to date?

Minus sign iconPlus sign icon As of March 2026, Biosion has raised $1.5K in funding. The last funding round occurred on Apr 23, 2023 for $1.5K.

When was Biosion founded?

Minus sign iconPlus sign iconBiosion was founded in 2017.

Biosion

Biotechnology ResearchJiangsu, China11-50 Employees

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. 

Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in four clinical trials, with the most advanced already in Phase 3. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. 

Biosion has operations in the US, Australia, and China. 
To learn more about Biosion visit www.biosion.com.

Section iconCompany Overview

Headquarters
Nanjing, Jiangsu 210061 China
Website
biosion.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $1.5K

    Biosion has raised a total of $1.5K of funding over 3 rounds. Their latest funding round was raised on Apr 23, 2023 in the amount of $1.5K.

  • $10M$25M

    Biosion's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $1.5K

    Biosion has raised a total of $1.5K of funding over 3 rounds. Their latest funding round was raised on Apr 23, 2023 in the amount of $1.5K.

  • $10M$25M

    Biosion's revenue is estimated to be in the range of $10M$25M

Company Leadership

  • Stylized image of a person
    A. Z.
    Vp Of Finance
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. M.
    Head Of Quality Management
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. C.
    Founder, Chairman And Ceo
    Phone icon
    Mobile Phone
  • Stylized image of a person
    E. B.
    Director, Business Development And Strategic Alliances
    Phone icon
    Mobile Phone
  • Stylized image of a person
    X. L.
    Senior Director
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    Y. S. P.
    Senior Director, Strategy, Bd And Operation
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. M.
    Director Of Protein Sciences
    Phone icon
    Mobile Phone
  • Stylized image of a person
    X. L.
    Senior Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. Y.
    Board Director, Chief Strategy Officer And Head Of China Bd
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.